A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Improvements in therapy for relapsed SCLC are much needed. Paclitaxel has been previously
tested and found to have significant single agent activity in relapsed SCLC, including in
refractory patients. Angiogenesis plays an important role in SCLC, increased VEGF levels are
associated with worse outcomes. Bevacizumab, a monoclonal antibody to VEGF, increase response
rates and survival when combined with chemotherapy agents compared with the chemotherapy
agent alone in NSCLC, breast cancer, and colorectal cancer. Paclitaxel plus bevacizumab, in
the dose and schedule proposed in this study, improves response rates and progression free
survival compared with paclitaxel alone in women with metastatic breast cancer. Therefore, we
will be testing the safety, feasibility, and efficacy of this regimen in patients with
chemosensitive relapsed SCLC.